Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

LAPLACE TIMI 57 - A Double-blind, Randomized, Placebo-controlled, Multicenter, Dose-ranging Study to Evaluate Tolerability and Efficacy of AMG 145 on LDL-C in Combination With HMG-CoA Reductase Inhibitors in Hypercholesterolemic Subjects

NCT01380730 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT01380730
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01380730 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
LAPLACE TIMI 57 - A Double-blind, Randomized, Placebo-controlled, Multicenter, Dose-ranging Study to Evaluate Tolerability and Efficacy of AMG 145 on LDL-C in Combination With HMG-CoA Reductase Inhibitors in Hypercholesterolemic Subjects
Lead sponsor
Amgen
Phase
Phase 2
Overall status
Completed
Start date
July 1, 2011
Completion date
April 5, 2012
Enrollment
631 (actual)
Sites
100

Conditions

As the registry lists them; a condition with its own page is linked.

hyperlipidemia